Search Results

Press Releases

DepYmed to Present at the 9th World Rett Syndrome Congress

October 3, 2024

·

4 min read

DepYmed to Meet with Investors at the BIO CEO and Investor Conference

DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes.

February 21, 2024

·

1 min read

Pharm Country

DepYmed to Meet with Investors at the 34th Annual Oppenheimer Healthcare Life Sciences Conference

DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes.

February 7, 2024

·

2 min read

Drug Development

DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome

DepYmed, Inc. (“DepYmed” or the “Company”) is a clinical-stage pharmaceutical company focused on developing transformative medicines for many poorly treated diseases that may benefit significantly by targeting the protein tyrosine phosphatase (PTP) family of enzymes.

March 19, 2024

·

3 min read

Pharm Country

DepYmed to Meet with Investors at the Life Sciences Summit in New York City October 11, 2023

DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes.

October 3, 2023

·

2 min read

Pharm Country

DepYmed to Meet with Investors at the BioFuture Conference in New York City October 4-6, 2023

DepYmed, Inc. is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase family of enzymes.

September 27, 2023

·

1 min read

Pharm Country

DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting

DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes.

May 31, 2023

·

3 min read

Pharm Country

DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting

DepYmed, Inc. is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase family of enzymes.

June 15, 2023

·

4 min read

Pharm Country

DepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Treatment of Rett Syndrome

DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology based upon targeting the protein tyrosine phosphatase (PTP) family of enzymes.

November 16, 2022

·

4 min read

Pharm Country

DepYmed Receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the Treatment of Wilson Disease

DepYmed Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology, based upon targeting the protein tyrosine phosphatase (PTP) family of enzymes.

May 23, 2022

·

3 min read